2,464 material Form 8-K filings that 2,079 companies we cover made with the SEC in November 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 1,081 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Alpha Pro Tech reported third quarter 2026 net sales of $16.6 million, up 12.3% from $14.8 million a year earlier, and net income of $1.9 million, or $0.19 per diluted share, up from $976,000 or $0.09. The Disposable Protective Apparel segment drove most of the sales gain, and the company reported $25.5 million in cash and no debt as of September 30, 2026.
Disposable Protective Apparel segment sales rose 30.2% to $7.2 million; Building Supply segment sales rose 1.7% to $9.4 million.
Gross profit margin was 41.8% in the third quarter of 2026, compared with 39.7% a year earlier.
Net income was $1.9 million, or $0.19 per diluted share, compared with $976,000, or $0.09 per diluted share, in the third quarter of 2025.
As of September 30, 2026, cash was $25.5 million, working capital was $52.1 million, and the company had no debt.
PowerCompute reported preliminary, unaudited October 2026 Bitcoin mining results, with 9.0 Bitcoin mined, up from 7.5 a year earlier and 8.1 in September. Active hashrate rose 11.4% to approximately 800 PH/s by October 31, after the company installed about 900 more efficient miners on its existing 26 megawatts of power.
Bitcoin mined in October 2026 was 9.0, up 20% from 7.5 in October 2025 and up 11.1% from 8.1 in September 2026.
Active hashrate reached approximately 800 PH/s at October 31, 2026, up 11.4% from approximately 718 PH/s at September 30, 2026.
The company sold 7.0 Bitcoin in October 2026 and held 65.7 Bitcoin at October 31, valued at approximately $5.1 million at about $77,000 per Bitcoin.
Energy sales at the Oklahoma site generated approximately $46,000 in October 2026.
Atossa Therapeutics reported a third-quarter 2026 net loss of $5.6 million, or $0.56 per share, compared with $8.7 million, or $1.01 per share, a year earlier. Operating expenses fell to $5.9 million from $9.3 million, and the filing reports no revenue. Cash and cash equivalents were $20.6 million at September 30, 2026, down from $41.3 million at December 31, 2025, and the company also disclosed a contingent value rights agreement tied to a possible future priority review voucher sale.
Q3 2026 net loss was $5.6 million ($0.56 per share), versus $8.7 million ($1.01 per share) in Q3 2025.
Nine-month 2026 net loss was $23.7 million ($2.58 per share), versus $23.8 million ($2.76 per share) a year earlier.
Cash and cash equivalents were $20.6 million at September 30, 2026, versus $41.3 million at December 31, 2025.
Under the CVR agreement dated October 8, 2026, holders are entitled to 25% of net proceeds from the first qualifying FDA priority review voucher sale, capped at $50 million; no voucher has been awarded.
Jerash Holdings (US), Inc. reported fiscal 2027 second-quarter results for the quarter ended September 30, 2026, with revenue up 19.8% and net income of $2.2 million, or $0.16 per diluted share, versus $479,000 a year earlier. The company also guided to fiscal third-quarter revenue of approximately $49 million to $51 million and a gross margin of approximately 16% to 17%.
Q2 revenue rose 19.8% to $50.3 million from $42.0 million; gross margin rose 320 basis points to 18.2%
Operating income was $3.1 million, up from $1.1 million; net income was $2.2 million, or $0.16 per diluted share
Q3 outlook: revenue of approximately $49 million to $51 million and gross margin of approximately 16% to 17%
Board approved a regular quarterly dividend of $0.05 per share on November 5, 2026, payable November 23, 2026 to holders of record as of November 16, 2026
Alliance Laundry reported third-quarter 2026 net revenues of $461 million, up 5% from a year earlier, and net income of $65 million compared with $33 million. It raised its full-year 2026 Adjusted EBITDA growth guidance to about 10%, the high end of its prior 8% to 10% range, while keeping revenue growth guidance at 6% to 7%. The company also repurchased $75 million of its common stock during the quarter.
Net revenues were $461 million, up 5% from $438 million; North America revenue rose 8% to $356 million.
Net income was $65 million versus $33 million; diluted EPS was $0.32 versus $0.19.
Adjusted EBITDA rose 14% to $127 million, with a 27.5% margin; a discrete tariff refund benefit helped results.
The company repurchased $75 million of stock and repaid $45 million of debt, reducing net leverage to 2.25x.
MasterCraft reported results for the first three months of its transition period ended October 4, 2026, following its May 15, 2026 merger with Marine Products and a change in fiscal year-end to December 31. Net sales, income from continuing operations, and Adjusted EBITDA all rose from the prior-year period, though gross margin fell 120 basis points, largely due to the Marine Products business. The company also gave outlook for the six-month transition period ending December 31, 2026.
Net sales were $154.1 million, up $85.1 million or 123.4%; excluding the Marine Products contribution, sales rose 37.4%, or $25.8 million.
Income from continuing operations was $12.1 million, or $0.50 per diluted share, versus $3.7 million, or $0.22, a year earlier.
Adjusted EBITDA was $20.1 million, a 13.0% margin, compared with $7.0 million and 10.1% in the prior-year period.
For the transition period, the company expects net sales of $293 million to $297 million, Adjusted EBITDA of $32 million to $34 million, and Adjusted EPS of $0.75 to $0.80.
Exagen reported third-quarter 2026 revenue of $18.4 million, up 7% from $17.2 million a year earlier, and a net loss of $6.3 million, compared with $7.1 million in the prior-year quarter. The company reiterated its full-year 2026 revenue guidance of $72 million to $75 million, which means results did not change its outlook.
Q3 2026 revenue $18.4 million vs. $17.2 million in Q3 2025; nine-month revenue $55.7 million, up 11%
Q3 2026 net loss $6.3 million vs. $7.1 million; nine-month net loss $13.5 million vs. $15.3 million
Full-year 2026 revenue guidance of $72 million to $75 million reiterated; cash and equivalents $28.1 million at September 30, 2026
Ambiq Micro reported third-quarter 2026 net sales of $38.1 million, up 110% from a year earlier, and a GAAP net loss of $7.1 million, narrowed from $9.0 million in the third quarter of 2025. The company expects fourth-quarter 2026 net sales of $43.5 million to $44.5 million, above the third-quarter level, and cited accelerating edge AI demand. Shareholders are seeing faster sales growth and a smaller loss, though the company used $25.4 million in operating cash over the first nine months of 2026.
Q3 2026 net sales were $38.1 million, up from $18.2 million in Q3 2025; GAAP gross margin was 46.7%.
GAAP net loss was $7.1 million in Q3 2026, compared with $9.0 million a year earlier.
Q4 2026 guidance: net sales of $43.5 million to $44.5 million and non-GAAP net loss per share of ($0.09) to ($0.03).
Cash and cash equivalents were $363.5 million at September 30, 2026, up from $140.3 million at December 31, 2025.
Energy Focus reported third quarter 2026 net sales of $4.8 million, up from $0.8 million a year earlier, and net income of $0.5 million, or $0.08 per share, compared with a net loss of $0.2 million in the third quarter of 2025. The company attributed the growth mainly to a Taiwan Uninterruptible Power Supply project with a new customer, and its forward-looking statements still cite substantial doubt about its ability to continue as a going concern.
Q3 2026 net sales were $4.8 million, up 481.2% year over year and up 28.1% from $3.7 million in Q2 2026.
Q3 2026 net income was $0.5 million, or $0.08 per diluted share, versus a Q2 2026 net loss of $0.9 million, or $(0.14) per share.
Nine-month 2026 net loss was $0.5 million, or $(0.08) per share, compared with $0.7 million, or $(0.12) per share, in the same period of 2025.
Cash was $3.3 million at September 30, 2026, including $0.9 million of short-term borrowings proceeds, versus $1.1 million at December 31, 2025.
CalciMedica reported third-quarter 2026 results, with a net loss of $1.7 million, or $0.24 per share, versus a net loss of $7.8 million, or $2.59 per share, a year earlier. The improvement was driven mainly by a noncash $3.1 million gain in other income, while operating expenses fell, and the filing reports cash of $13.8 million as of September 30, 2026, which the company expects to fund its operating plan into the second half of 2027.
Q3 2026 net loss was $1.7 million ($0.24 per share), compared with $7.8 million ($2.59 per share) in Q3 2025.
Q3 2026 total other income was $3.1 million, mainly from a noncash change in fair value of financial instruments.
Q3 2026 research and development expenses were $2.3 million, down from $3.9 million, and general and administrative expenses were $2.4 million, up from $1.8 million.
Cash, cash equivalents and short-term investments were $13.8 million as of September 30, 2026.
Cullinan Therapeutics reported third quarter 2026 results, with a net loss of $49.4 million, down from $50.6 million a year earlier, as research and development and general and administrative expenses both declined. The company said its cash and investments of $313.8 million as of September 30, 2026 provide runway into 2029 under its current operating plan, though cash was down from $439.0 million at December 31, 2025.
Q3 2026 net loss was $49.4 million, compared with $50.6 million in Q3 2025; nine-month net loss was $152.8 million, compared with $169.2 million
Q3 2026 research and development expenses were $40.2 million, versus $42.0 million a year earlier
Cash, cash equivalents, investments, and interest receivable were $313.8 million at September 30, 2026, versus $439.0 million at December 31, 2025, with runway into 2029
908 Devices reported third-quarter 2026 revenue of $19.0 million, up 35% from a year earlier, and a net loss from continuing operations of $4.6 million, down from $14.9 million. The company raised the low end of its full-year 2026 revenue guidance to $68.5 million to $70.0 million. A $11.0 million noncash reduction in contingent consideration expense helped narrow the loss, and the company reported no debt outstanding.
Q3 2026 revenue was $19.0 million, up from $14.0 million a year earlier; GAAP gross margin was 53%, unchanged from the prior year.
Operating expenses fell to $15.5 million from $23.7 million, mainly due to an $11.0 million noncash reduction in contingent consideration expense.
2026 revenue guidance is now $68.5 million to $70.0 million, up from $68.0 million to $70.0 million at the low end.
Cash and marketable securities were $99.1 million as of September 30, 2026, with no debt outstanding.
Humacyte reported third-quarter 2026 results with Symvess sales of $1.0 million, up from $0.4 million in the second quarter and $0.7 million a year earlier. The quarterly net loss narrowed to $15.5 million, or $0.06 per share, from $17.5 million, or $0.11 per share, a year earlier, but the nine-month net loss widened to $70.0 million, mainly due to a non-cash remeasurement of the contingent earnout liability.
Q3 2026 Symvess sales were $1.0 million, versus $0.4 million in Q2 2026 and $0.7 million in Q3 2025.
Q3 2026 net loss was $15.5 million ($0.06 per share), compared with $17.5 million ($0.11 per share) in Q3 2025.
Nine-month 2026 net loss was $70.0 million, versus $16.0 million in the prior-year period, driven by a non-cash earnout remeasurement.
October 2026 Symvess sales were $0.8 million; cash and equivalents were $64.9 million as of September 30, 2026.
Protalix reported third-quarter 2026 total revenue of $21.9 million, up from $17.9 million a year earlier, and net income of $4.0 million, or $0.05 per share, compared with $2.4 million, or $0.03 per share. Nine-month revenue reached $75.6 million versus $43.6 million, and the company reaffirmed 2026 total revenue guidance of $78.0 million to $83.0 million, which includes a $25.0 million Chiesi milestone received in the first quarter. For shareholders, revenue and profit rose year over year, cash and short-term deposits totaled $48.5 million at September 30, 2026, and the company reported no outstanding debt or warrants.
Q3 2026 net income was $4.0 million ($0.05 per share, basic and diluted) versus $2.4 million ($0.03 per share) in Q3 2025
Nine-month 2026 total revenue was $75.6 million versus $43.6 million, including a $25.0 million Chiesi milestone received in Q1 2026
2026 total revenue guidance of $78.0 million to $83.0 million was reaffirmed, with the company expecting to meet or exceed these ranges
Cash, cash equivalents and short-term bank deposits were $48.5 million at September 30, 2026; the company has no outstanding debt or warrants
Sally Beauty Holdings reported fourth-quarter fiscal 2026 results for the period ended September 30, 2026, with net sales of $953 million, up 0.6%, and GAAP diluted earnings per share of $0.60, up 22%. The company also issued initial fiscal 2027 guidance calling for adjusted diluted EPS of $2.20 to $2.30, compared with $2.08 in fiscal 2026. The guidance is an initial forecast rather than a revision, and it points to higher sales and adjusted earnings per share in fiscal 2027.
Q4 net sales were $953 million, up 0.6%; consolidated comparable sales rose 0.9%.
Q4 GAAP diluted EPS was $0.60, up 22%; adjusted diluted EPS was $0.62, up 13%.
Fiscal 2027 guidance: net sales of $3.77 billion to $3.81 billion and adjusted diluted EPS of $2.20 to $2.30.
Full-year cash flow from operations was $323 million; the company repurchased $113 million of shares during fiscal 2026.
TransDigm reported fourth-quarter fiscal 2026 net sales of $2,988 million, up 23%, and EPS of $10.33, up 33%, while quarterly net income fell 4% to $586 million on higher interest and tax expense. The company also issued fiscal 2027 guidance calling for net sales of $11,950 million to $12,150 million and EPS of $42.06 to $42.91, which shareholders can compare against the fiscal 2026 results.
Q4 net sales $2,988 million, up 23% from $2,437 million; EPS $10.33, up 33% from $7.75.
Q4 net income $586 million, down $23 million or 4%; adjusted EPS $12.44, up 15% from $10.82.
Fiscal 2027 guidance: net sales $11,950 million to $12,150 million; EPS $42.06 to $42.91; adjusted EPS $47.09 to $47.94.
Company returned $943 million through buybacks in Q4 and $2.8 billion for fiscal 2026.
Ampco-Pittsburgh reported third quarter 2026 net sales of $111.7 million, up 3% from $108.0 million a year earlier, and net income attributable to the company of $0.5 million, or $0.02 per share, compared with a net loss of $2.2 million, or $0.11 per share, in the prior-year quarter. The company also reduced net debt by $19.5 million in the quarter, to $111.0 million, which strengthens its balance sheet for shareholders.
Net sales were $111.7 million, versus $108.0 million in the third quarter of 2025; Air and Liquid Processing sales rose 17% to $42.8 million
Net income attributable to Ampco-Pittsburgh was $0.5 million, or $0.02 per share, versus a net loss of $2.2 million, or $0.11 per share, a year earlier
Adjusted EBITDA rose 2% to $9.4 million; adjusted EBITDA margin was 8.4%, compared with 8.5% in the prior-year period
Net debt fell to $111.0 million at September 30, 2026, down $19.5 million from $130.5 million at June 30, 2026
Solidion Technology reported third-quarter 2026 results, with revenue of $41,638 compared with $9,350 a year earlier and net income of approximately $244,000 compared with a net loss of $4.1 million in the prior-year period. Cash and cash equivalents were $26.2 million at September 30, 2026, and total liabilities fell about 40% from year-end 2025, which the company says supports its capacity to pursue acquisitions.
Q3 2026 revenue was $41,638, up from $9,350 in Q3 2025; basic EPS was $0.02 versus a loss of $1.33 per share.
Net income was approximately $244,000 for the quarter, compared with a net loss of $4.1 million in the prior-year period.
Cash and cash equivalents were $26.2 million at September 30, 2026, down from $27.7 million at June 30, 2026.
On September 13, 2026, the Board authorized repurchases of up to $1.0 million of common stock.
Mueller Water Products furnished an updated investor presentation dated November 11, 2026, which reports results for the fiscal year ended September 30, 2026. Net sales were $1,475.0 million, up from $1,429.7 million in FY2025, and net income rose to $221.9 million from $191.7 million. Shareholders get a fuller view of profit and cash flow, which the company says reflects a third consecutive year of record results.
FY2026 net sales of $1,475.0 million, compared with $1,429.7 million in FY2025.
Net income of $221.9 million, or $1.41 per diluted share, compared with $191.7 million, or $1.22 per share.
Adjusted EBITDA of $372.2 million, compared with $326.2 million; adjusted EPS of $1.57, compared with $1.31.
Free cash flow of $207.3 million, compared with $172.0 million; strategic reorganization and other charges were $27.8 million.
EquipmentShare reported third-quarter 2026 results for the period ended September 30, 2026, with total revenue up 55% year over year to $1,468 million and net income of $20 million, compared with $6 million a year earlier. Adjusted Core EBITDA rose 40% to $594 million, and management said it is confident in its full-year 2026 outlook and sees an opportunity to outperform it. For shareholders, both headline revenue and profit grew, though GAAP net income remains small relative to revenue and interest expense was $88 million in the quarter.
Total revenue rose 55% to $1,468 million from $945 million; Rental Segment revenue rose 49% to $1,113 million.
Net income was $20 million versus $6 million; Adjusted Net Income, which excludes $26 million of IPO Founders Awards stock compensation, was $46 million.
Adjusted Core EBITDA increased 40% to $594 million; net leverage fell to 3.4x from 3.7x a year earlier.
Current 2026 guidance ranges include total revenue of $5,808 million to $6,045 million and Adjusted Core EBITDA of $2,136 million to $2,224 million.
Tidewater reported third-quarter 2026 revenue of $360.4 million, up from $341.1 million a year earlier, and net income attributable to the company of $17.5 million, or $0.35 per diluted share, compared with a loss of $0.8 million a year earlier. The company also initiated 2027 revenue guidance of $1.70 to $1.75 billion and updated its 2026 revenue guidance to $1.43 to $1.44 billion, while closing a $500 million all-cash acquisition of Wilson Sons Ultratug Offshore.
Q3 2026 revenue of $360.4 million, up 5.3% from the second quarter of 2026
Q3 2026 net income of $17.5 million ($0.35 per diluted share), versus a $0.8 million loss a year earlier
Nine-month 2026 net income of $45.3 million, down from $114.8 million in the first nine months of 2025
2027 revenue guidance of $1.70 to $1.75 billion; 2026 revenue guidance updated to $1.43 to $1.44 billion
GMR Solutions reported third quarter 2026 net revenue of $1,595.6 million, up 5.9%, and net income of $135.6 million, up 81.7%, and updated its full year 2026 guidance. Adjusted EBITDA rose 4.2% to $356.6 million in the quarter, but nine-month Adjusted EBITDA grew only 0.4%, and the filing does not state the prior guidance, so the direction of the update cannot be judged from it.
Q3 2026 net revenue $1,595.6 million, up 5.9% from $1,506.9 million; net income $135.6 million, up from $74.6 million
Q3 2026 Adjusted EBITDA $356.6 million, up 4.2%; nine-month Adjusted EBITDA $946.1 million, up 0.4%
Updated full year 2026 guidance: net revenue $5,900 million to $6,050 million; Adjusted EBITDA $1,135 million to $1,195 million
Liquidity of approximately $999.3 million at September 30, 2026, including $298.0 million of cash; $200.0 million of term loan repaid in a September 17, 2026 repricing
Elmet Group reported third-quarter 2026 results for the period ended October 2, 2026, with revenue up 55.6% to $79.6 million and net income of $8.3 million, or $0.24 per diluted share, compared with $1.6 million, or $0.08, a year earlier. Gross margin rose to 31.3% and open order backlog reached a company record $347.4 million, though nine-month net income fell to $3.5 million from $4.0 million and the release gives no new guidance.
Q3 revenue was $79.6 million versus $51.1 million a year earlier; gross profit margin was 31.3% versus 21.7%.
Adjusted EBITDA was $17.0 million, or 21.3% of revenue, versus $7.4 million, or 14.5%, in Q3 2025.
Q3 net income was $8.3 million, or $0.24 per diluted share, versus $0.08 per diluted share a year earlier.
Nine-month net income was $3.5 million, or $0.10 per diluted share, versus $4.0 million, or $0.20, for the nine months ended September 30, 2025.
AST SpaceMobile reported third quarter 2026 revenue of $42.3 million, up from $14.7 million a year earlier, and a net loss attributable to common stockholders of $132.4 million, or $0.44 per share, compared with $122.9 million, or $0.45 per share, in the third quarter of 2025. The company said it remains on target for its revenue guidance of $150.0 million to $200.0 million and cited about $1.0 billion in non-dilutive Japanese government funding for satellite manufacturing and launch.
Q3 2026 total revenue was $42.3 million versus $14.7 million in Q3 2025; nine-month revenue was $88.6 million versus $16.6 million
Net loss attributable to common stockholders was $132.4 million, or $0.44 per share, versus $122.9 million, or $0.45 per share, a year earlier
Company remains on target for 2026 revenue guidance of $150.0 million to $200.0 million
Cash, cash equivalents and restricted cash were approximately $3.2 billion as of September 30, 2026
Bally's preliminary third-quarter 2026 consolidated revenue rose 21.7% year over year to $807.6 million, with growth led by Bally's Intralot B2C and North America Interactive. The company said it expects to file a Rule 12b-25 extension and its Form 10-Q within the extension period, and the figures remain subject to its close process. The results are preliminary and unaudited, so shareholders should watch for the final 10-Q.
Preliminary Q3 2026 revenue was $807.6 million, up from $663.7 million a year earlier
Bally's Intralot B2C revenue rose 22.8% to $257.5 million, while its Adjusted EBITDAR fell to $77.0 million from $86.4 million
The company expects to file a Rule 12b-25 extension and its 10-Q within the extension period
On October 1, 2026, Bally's closed Bronx project financing, receiving $400 million with $160 million more available for future draws
Mesa Laboratories reported fiscal second-quarter revenue of $62.3 million, up 2.6%, and net income of $4.3 million, up 75.3%, or $0.75 per diluted share versus $0.45 a year earlier. The company also issued its first fiscal 2027 guidance, calling for revenue of $250 million to $255 million and adjusted EBITDA of $66 million to $68 million, and authorized a share repurchase of up to $40 million.
Q2 revenue $62.3 million, up 2.6%; adjusted EBITDA $17.3 million, up 21.1%, or 27.8% of revenue
Fiscal 2027 guidance (year ending March 31, 2027): revenue $250 million to $255 million; adjusted EBITDA $66 million to $68 million
Board terminated its 2005 buyback program on November 4, 2026 and authorized up to $40 million in repurchases through December 31, 2028
Savings Plan announced October 13, 2026 expects total pre-tax restructuring charges of $2.6 million to $3.4 million, mainly in the second half of fiscal 2027
Babcock & Wilcox reported third quarter 2026 revenue of $290.8 million, up from $139.2 million a year earlier, and net income of $93.9 million, up from $35.1 million. Net income was lifted by an $85.1 million change in the fair value of customer warrants, and adjusted net income was $4.8 million. The company reiterated its 2026 Adjusted EBITDA target of $80.0 million to $105.0 million and issued a 2027 Adjusted EBITDA target of $125 million to $140 million.
Q3 2026 revenue of $290.8 million vs. $139.2 million in Q3 2025; Adjusted EBITDA of $17.7 million vs. $9.4 million
Net income of $93.9 million includes an $85.1 million change in fair value of customer warrants; adjusted net income was $4.8 million
Basic EPS of $0.61 vs. $0.30 in Q3 2025; Q3 bookings of $228 million and backlog of $2.5 billion
2026 Adjusted EBITDA target of $80.0 million to $105.0 million reiterated; 2027 target of $125 million to $140 million issued
P3 Health Partners reported third quarter 2026 revenue of $396 million, up 15% from a year earlier, and net income of $30.8 million versus a net loss of $69.5 million in the prior-year quarter. The company raised the low end of its full-year 2026 Adjusted EBITDA guidance to $90 million, moving the midpoint to $100 million, though the quarter also benefited from payer settlements and prior-year development.
Q3 2026 total revenue was $396 million, up 15% from $345 million a year earlier.
Q3 2026 Adjusted EBITDA was $20.9 million, compared with a loss of $45.9 million in Q3 2025.
Full-year 2026 Adjusted EBITDA guidance is now $90 million to $110 million, up from a lower low end.
Q3 medical margin of $43.9 million included favorable payer settlements; excluding these items it was $35.0 million.
AbCellera reported third-quarter 2026 results, with total revenue of $10.6 million versus $9.0 million a year earlier and a net loss of $40.8 million, or $(0.13) per share, down from $57.1 million, or $(0.19) per share. The company said it had over $890 million in total available liquidity as of September 30, 2026, including a $200 million share offering that closed August 14, 2026 at $9.75 per share.
Total revenue of $10.6 million in Q3 2026, compared with $9.0 million in Q3 2025
Net loss of $40.8 million, or $(0.13) per share, compared with $57.1 million, or $(0.19) per share, in Q3 2025
R&D expenses of $43.5 million, down from $55.0 million; SG&A expenses of $13.6 million, down from $25.0 million
Positive top-line Phase 2 data for ABCL635 announced in Q3; Phase 1 top-line data for ABCL575 announced after quarter end
FutureFuel reported third-quarter 2026 results on November 9, 2026. Revenue rose 361% to $104.7 million, driven by biofuel volume and pricing, and the net loss narrowed to $8.4 million from $9.2 million, although the company still posted a gross loss and a shrinking cash balance. The company expects positive Adjusted EBITDA in the fourth quarter and for full-year 2026, after a nine-month Adjusted EBITDA loss of $6.9 million.
Q3 2026 total revenue was $104.7 million, up from $22.7 million in Q3 2025; biofuel revenue was $87.8 million.
Net loss was $8.4 million, or $0.19 per diluted share, compared with a $9.2 million net loss in Q3 2025.
Q3 Adjusted EBITDA was a loss of $4.9 million; the company expects fourth-quarter Adjusted EBITDA of approximately $7 million.
Cash and cash equivalents were $21.3 million at September 30, 2026, down from $34.3 million at June 30, 2026.
Coherus Oncology reported third quarter 2026 net revenue from continuing operations of $14.3 million, up from $11.6 million a year earlier, and a narrower net loss from continuing operations of $38.9 million, or $(0.25) per share, versus $44.5 million, or $(0.38) per share. The company also announced a strategic prioritization plan that focuses tagmokitug development on esophageal cancer and reduces headcount by about 30%, with the CFO saying these benefits will be realized over the next two quarters.
Q3 2026 net revenue from continuing operations was $14.3 million, versus $11.6 million in Q3 2025; LOQTORZI revenue was $14.0 million, up 25% from $11.2 million.
Q3 2026 GAAP net loss from continuing operations was $38.9 million, or $(0.25) per share, versus $44.5 million, or $(0.38) per share, in Q3 2025.
Right-sizing reduces headcount by about 30% and is expected to lower core cash burn by $6 million to $7 million per quarter.
Cash, cash equivalents and marketable securities were $83.6 million at September 30, 2026, versus $172.1 million at December 31, 2025.
Lincoln Educational Services reported third-quarter 2026 revenue of $159.2 million, up 12.6% from $141.4 million, with net income of $4.7 million, up from $3.8 million. The company raised its full-year 2026 revenue guidance to $600.0 million to $605.0 million while reiterating its adjusted EBITDA guidance of $76.0 million to $80.0 million.
Q3 2026 revenue of $159.2 million, up from $141.4 million; net income of $4.7 million, up from $3.8 million
Diluted EPS of $0.15 versus $0.12; adjusted EBITDA of $17.4 million, up 30.8%
2026 revenue guidance raised to $600.0 million to $605.0 million; student start growth guidance narrowed to 10% to 12%
Board raised the share repurchase authorization by $30 million to $70 million total, with more than $37 million remaining
ImageneBio reported third quarter 2026 results, with a net loss of $15.6 million, or $0.91 per share, down from $24.8 million, or $2.91 per share, a year earlier. The company had no revenue in either period, and lower research and development and general and administrative expenses drove the smaller loss. It ended the quarter with $126.6 million in cash, cash equivalents and marketable securities, which it expects will fund planned operations into the first quarter of 2028.
Net loss was $15.6 million for the three months ended September 30, 2026, compared with $24.8 million a year earlier.
Net loss per share was $0.91, compared with $2.91 a year earlier.
R&D expenses fell to $11.3 million from $15.2 million, and G&A expenses fell to $6.0 million from $11.0 million.
Cash position was $126.6 million as of September 30, 2026, with funding expected into the first quarter of 2028.
Atea Pharmaceuticals reported a third-quarter 2026 net loss of $32.2 million, or $0.40 per share, down from $42.0 million, or $0.53 per share, a year earlier, as research and development spending fell. The company also secured a credit facility with Hercules Capital of up to $200 million, of which $65 million was drawn on November 6, 2026, and said current resources fund operations into mid-2028.
Net loss was $32.2 million, or $0.40 per share, for the three months ended September 30, 2026, versus $42.0 million, or $0.53 per share, a year earlier.
Cash, cash equivalents and marketable securities were $191.2 million at September 30, 2026, versus $301.8 million at December 31, 2025.
Hercules Capital facility of up to $200 million; $65 million drawn at closing on November 6, 2026, with up to $135 million more subject to milestones.
Phase 3 C-BEYOND trial met its primary endpoint: 93.91% SVR for BEM/RZR versus 94.75% for Epclusa; C-FORWARD topline results expected in early 2027.
AMCON Distributing reported results for the fiscal year ended September 30, 2026, with diluted earnings per share of $2.52 compared with $0.62 in the prior year. Sales rose to $3.12 billion from $2.82 billion, and the retail health food segment posted an operating loss while the wholesale segment reported operating income.
Net income available to common shareholders was $2.4 million, compared with $0.6 million in fiscal 2025.
Sales were $3.12 billion, compared with $2.82 billion in fiscal 2025.
Wholesale distribution segment operating income was $25.5 million; retail health food segment operating loss was $0.6 million.
Shareholders' equity was $117.0 million at September 30, 2026.
Verde Clean Fuels reported third-quarter 2026 results, with a net loss of $2.0 million, or $(0.04) per Class A share, compared with a net loss of $2.3 million, or $(0.06) per share, a year earlier. The company attributed the smaller loss mainly to cost savings, partly offset by higher share-based compensation, and reported $52.6 million in cash and no debt as of September 30, 2026.
Q3 2026 net loss of $2.0 million vs. $2.3 million in Q3 2025; diluted loss per Class A share of $(0.04) vs. $(0.06)
Nine-month 2026 net loss of $6.3 million vs. $7.6 million in the same period of 2025; loss per share of $(0.14) vs. $(0.21)
Cash and cash equivalents of $52.6 million and no debt as of September 30, 2026
The company said it continues to evaluate strategic alternatives and opportunities to deploy its STG+ technology
AlTi Global reported third-quarter 2026 results in an investor presentation furnished under Item 2.02 and Item 7.01. Revenue edged up 1% year over year, operating expenses fell 25%, and the net loss from continuing operations narrowed sharply, which points to improved profitability for shareholders. The filing contains no guidance update.
Revenue was $58 million, up 1% from $57.2 million a year earlier, with management fees up 7% to $55 million
Total operating expenses fell 25% year over year to $64 million
Operating loss narrowed to $6 million from $28.5 million a year earlier; net loss from continuing operations was $11.4 million versus $87.0 million
Adjusted EBITDA was $6.2 million, up 1% year over year, with a 10.8% margin
EVI Industries reported results for the first fiscal quarter of 2027, ended September 30, 2026, with revenue up 4.3% to a record $112.9 million and net income up 108% to $3.8 million. Net debt rose to $76.7 million from $44.2 million at June 30, 2026, mainly from borrowings for the Sudsies acquisition, which matters to shareholders because it increases the company's leverage.
Revenue increased 4.3% to $112.9 million; gross profit rose 12% to $38.0 million
Operating income increased 75% to $6.2 million; net income increased 108% to $3.8 million
Diluted earnings per share were $0.24, compared with $0.11 a year earlier
Net debt was $76.7 million at September 30, 2026, compared with $44.2 million at June 30, 2026
Groupon reported third-quarter 2026 results for the period ended September 30, 2026, with global revenue up 2% and billings up 6% year over year. The loss from continuing operations narrowed to $0.8 million from $117.8 million a year earlier, while Adjusted EBITDA fell to $14.7 million from $17.5 million, and the company gave full-year 2026 revenue guidance of $500 million to $503 million.
Global revenue rose 2% and billings rose 6% year over year in Q3 2026; North America Local Revenue was flat.
Loss from continuing operations was $0.8 million, compared with $117.8 million in Q3 2025.
Adjusted EBITDA was $14.7 million, compared with $17.5 million a year earlier; free cash flow was negative $45.8 million.
For 2026, the company expects revenue of $500 million to $503 million and Adjusted EBITDA of $60 million to $65 million; management will host an investor update on December 8, 2026.
Life360 reported third-quarter 2026 total revenue of $174.1 million, up 40% from a year earlier, with net income of $22.5 million, up 130%, including a $17.5 million investment fair value gain. The company narrowed its full-year 2026 guidance for consolidated revenue to $665 million to $681 million and for Adjusted EBITDA to $132 million to $138 million, and reported $44.4 million in share repurchases to date.
Q3 2026 total revenue of $174.1 million, up 40% YoY; advertising revenue of $25.4 million, up 250% YoY
Net income of $22.5 million, up 130% YoY, including a $17.5 million net gain on fair value of investments
Adjusted EBITDA of $34.6 million, up 41% from $24.5 million in Q3 2025
FY26 consolidated revenue guidance of $665 million to $681 million, versus the prior $650 million to $685 million; Adjusted EBITDA guidance of $132 million to $138 million, narrowed from $130 million to $140 million
Clearway Energy reported third-quarter 2026 revenue of $522 million, up from $429 million a year earlier, and net income of $123 million, up from $60 million. The company reaffirmed its 2026 CAFD guidance of $430 million to $470 million and set a 2027 CAFD guidance range of $520 million to $590 million. Net income attributable to Clearway Energy, Inc. fell to $51 million from $232 million, so shareholder-level earnings were lower.
Q3 2026 revenue $522 million vs. $429 million in Q3 2025; Adjusted EBITDA $435 million vs. $385 million
Net income attributable to Clearway Energy, Inc. was $51 million ($0.42 per share) vs. $232 million ($1.97 per share) a year earlier
2026 CAFD guidance reaffirmed at $430 million to $470 million; 2027 CAFD guidance set at $520 million to $590 million
Board declared a quarterly dividend of $0.4824 per share payable December 15, 2026, to holders of record as of December 1, 2026
Greystone Housing Impact Investors LP reported third-quarter 2026 net income of $3.2 million, or $0.09 per BUC, compared with $851,000 in the same quarter of 2025, and total revenues of $21.95 million, up from $21.11 million. Cash Available for Distribution was $3.8 million, or $0.17 per BUC, versus $0.18 a year earlier, and the quarterly distribution was $0.14 per BUC, down from $0.30 in the prior-year quarter. The partnership is reducing its market-rate multifamily joint venture equity investments and redeploying capital into tax-exempt mortgage revenue bonds, and it said the pace of sales will affect near-term results.
Q3 2026 net income of $3.2 million, or $0.09 per BUC, versus $851,000, or $(0.01) per BUC, in Q3 2025
Total revenues of $21.95 million for Q3 2026, versus $21.11 million a year earlier
Quarterly distribution of $0.14 per BUC, paid October 30, 2026, versus $0.30 declared in Q3 2025
Five MRBs tied to a single borrower were behind on debt service as of September 30, 2026; payments were received on four of the five as of the filing date
Octave Specialty Group reported third quarter 2026 results, with total revenue up 28% to $85.3 million and a net loss from continuing operations attributable to shareholders of $13.8 million, compared with $31.7 million a year earlier. The company also said that after quarter end, Everspan agreed to sell its Providence Washington Insurance Company subsidiary, which it expects to simplify its operating structure and strengthen its capital base.
Total revenue rose 28% to $85.3 million from $66.6 million in the third quarter of 2025.
Net loss from continuing operations attributable to shareholders was $13.8 million, or $0.31 per diluted share, versus $31.7 million, or $0.65 per share, a year earlier.
Adjusted EBITDA to shareholders was $3.3 million, compared with a loss of $2.9 million in the prior-year period.
Management expects market softening to continue into 2027; the earnings call is scheduled for November 10, 2026, at 8:30am ET.
OraSure Technologies reported third-quarter 2026 results, with total net revenues up 14% year over year to $30.9 million and a GAAP net loss of $13.1 million, compared with $13.7 million a year earlier. The company guided fourth-quarter 2026 revenue to $30.0 million to $32.0 million and expects full-year 2026 growth of 4.7% at the midpoint of the range. For shareholders, the quarter shows higher sales and a smaller loss, but nine-month revenue rose only 1%.
Q3 2026 total net revenues were $30.9 million, up 14% from $27.1 million in Q3 2025.
GAAP gross margin was 45.2%, compared with 43.5% a year earlier; GAAP net loss was $13.1 million versus $13.7 million.
Q4 2026 revenue guidance is $30.0 million to $32.0 million; full-year 2026 growth is 4.7% at the midpoint.
Cash and cash equivalents were $148 million as of September 30, 2026, after $7.0 million of nine-month share repurchases.
Qualys reported third-quarter 2026 revenue of $188.0 million, up 11% from $169.9 million a year earlier, and GAAP diluted earnings of $1.62 per share versus $1.39. The company raised its full-year 2026 revenue guidance to $736.9 million-$738.9 million from $732.0 million-$738.0 million and its GAAP EPS guidance to $6.08-$6.15 from $5.76-$5.90, which points to a higher outlook for shareholders.
Q3 revenue $188.0 million, up 11% from $169.9 million; GAAP net income $57.2 million
GAAP diluted EPS $1.62 vs. $1.39; non-GAAP diluted EPS $2.12 vs. $1.86
Full-year 2026 revenue guidance raised to $736.9 million-$738.9 million; GAAP EPS guidance raised to $6.08-$6.15
Q4 2026 revenue guidance set at $191.0 million-$193.0 million, 9% to 10% growth
Lucid reported third quarter 2026 revenue of $350.3 million, up from $336.6 million a year earlier, and a net loss of $830.9 million, down from $978.4 million. Free cash flow consumption fell 30% sequentially to $1.04 billion, and a $1.75 billion increase to the PIF-backed DDTL facility, announced with the results, lifts pro forma liquidity to $3.75 billion. Lucid says this liquidity should fund operations into Q4 2027, through the Midsize production start.
Q3 2026 revenue was $350.3 million, up from $336.6 million in Q3 2025; net loss per share was $(2.74) versus $(3.31).
Free cash flow consumption declined 30% sequentially to $1.04 billion.
Total liquidity was $2.0 billion at quarter end, or $3.75 billion pro forma for the $1.75 billion DDTL increase.
Year-to-date cash flow improvement savings reached $0.8 billion against a full-year target of $1.4 billion.
PubMatic reported third-quarter 2026 revenue of $79.6 million, up 17% from a year earlier, and GAAP net income of $5.5 million, or $0.11 per diluted share, compared with a net loss of $6.5 million in the prior-year quarter. Its Board also authorized an additional $150 million for share repurchases and extended the program through December 31, 2028, bringing the total available to approximately $198 million.
Q3 2026 revenue was $79.6 million, up 17% year over year; adjusted EBITDA was $26.0 million, versus $11.2 million in Q3 2025.
GAAP net income was $5.5 million ($0.11 per diluted share), compared with a net loss of $6.5 million ($0.14 per share) in Q3 2025.
Q4 2026 revenue guidance is $91 million to $93 million, and full-year 2026 revenue guidance is $312 million to $314 million.
On November 9, 2026, the Board authorized $150 million of additional repurchases, with the program running through December 31, 2028.
Trump Media & Technology Group reported third-quarter 2026 revenue of $3.0 million, up from $1.0 million a year earlier, and net income of $409.7 million. Most of the profit came from non-cash gains on digital assets and equity securities, and Adjusted EBITDA was a $12.3 million loss, narrower than the $29.1 million loss in the third quarter of 2025.
Revenue rose 205% year over year, driven by $1.8 million of Media segment subscription growth from Truth API, which launched August 1, 2026, and Truth+, plus $0.2 million in Truth.Fi management fees.
Net income of $409.7 million included $496.1 million of net realized and unrealized gains on digital assets, pledged digital assets and equity securities.
Adjusted EBITDA was a $12.3 million loss in the third quarter of 2026, compared with a $29.1 million loss in the third quarter of 2025.
Legal fees fell to $2.4 million from $20.3 million, and cash used in operating activities for the nine months ended September 30, 2026 was $28.4 million.
Zymeworks reported third quarter 2026 net income of $173.7 million, compared with a net loss of $19.6 million a year earlier, driven mainly by a $250 million milestone from Jazz Pharmaceuticals after the U.S. approval of Ziihera for first-line HER2-positive gastroesophageal adenocarcinoma. The company raised its 2026 total revenue guidance to $337 million to $351 million from $278 million to $292 million. Higher selling, general and administrative costs tied to the Theravance Biopharma acquisition partly offset the gain.
Q3 2026 total revenue was $256.5 million, compared with $27.6 million in Q3 2025.
Q3 2026 diluted earnings per share were $2.28, compared with a loss of $0.26 per share in Q3 2025.
2026 adjusted EBITDA guidance was raised to $176 million to $190 million from $114 million to $128 million.
SG&A expenses rose to $42.7 million from $14.1 million, mainly due to Theravance Biopharma acquisition costs, which closed September 23, 2026.
Onto Innovation reported fiscal third-quarter 2026 revenue of $409.7 million, up 87.8% from a year earlier, with GAAP net income of $46.8 million, or $0.95 diluted EPS, versus $0.57 a year earlier. The company also guided fourth-quarter 2026 revenue to $430 million to $450 million and non-GAAP diluted EPS to $2.59 to $2.79, while a $40.8 million unrealized loss on its Rigaku investment weighed on GAAP results.
Q3 revenue of $409.7 million vs. $218.2 million in Q3 2025; non-GAAP diluted EPS of $2.44 vs. $0.92
GAAP net income of $46.8 million includes a $40.8 million unrealized loss on the Rigaku investment
Q4 2026 guidance: revenue of $430 million to $450 million; GAAP diluted EPS of $1.95 to $2.07
Cash, equivalents and marketable securities of $1.25 billion at September 30, 2026; backlog above $1.3 billion
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.